(Raising $5.4M in a Series Seed Round - "we will deploy the proceeds from the round for our Phase I clinical trial with our lead drug candidate." Sept.2022 ) Toragen Biotechnologies is focused on developing, repurposing and commercializing uniquely selective cancer drugs targeting cancers caused by the human papillomavirus (HPV). HPV associated cancers include Head and Neck Cancer, Cervical Cancer, and multiple other Genitourinary and Gastrointestinal Cancers. We are developing drugs designed to inhibit HPV oncogenes, the root cause of malignant transformation in these cancers. It is our intent that these drugs will be more selective for malignant cells and better tolerated by patients than traditional cytotoxic and radiation cancer therapy. Our drugs interfere with the ability of the HPV virus to inhibit the immune system and will thus enhance the ability of the immune system to eradicate these cancers and potentially augment the activity of existing immunotherapies for cancer.
